 |
|
|
| |
Preclinical characterization of CC-31244, a pan-genotypic, potent NS5B non-nucleoside inhibitor for the treatment of chronic hepatitis C
|
| |
| |
Reported by Jules Levin
AASLD 2015 Nov 13-17 San Francisco
Jacobson1, M Feese1, H Xiao1, E Sanchez1, L Uher1, B Lin1, R Tomkiewicz1, T Whitaker2, T McBrayer2, L Pascual2, J Pattassery2, S Lee1 1 Cocrystal Pharma Inc., Bothell, WA 98011 and 2 Cocrystal Pharma Inc., Tucker, GA 30084
|
| |
|
|
|
|
|
